Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed’s cloud-connected ventilators and proprietary software generate reams of regulatory data, making its disclosures dense even for seasoned analysts. If you have ever sifted through a 300-page report looking for AirSense sales or FDA recall language, you know the challenge. Stock Titan surfaces what matters in seconds, turning complicated respiratory-device statements into clear talking points.
Our AI reads every ResMed annual report 10-K simplified, scans each ResMed quarterly earnings report 10-Q filing, and flags fresh ResMed 8-K material events explained the moment they hit EDGAR. Want management sentiment? Real-time alerts track ResMed insider trading Form 4 transactions and the companion ResMed executive stock transactions Form 4 data stream. Policy votes and pay packages are covered in the ResMed proxy statement executive compensation section. All documents sit one click away, while concise paragraphs answer most popular searches such as understanding ResMed SEC documents with AI or “How do I find the latest ResMed Form 4 insider transactions real-time?”
Use these insights to:
- Compare PAP device revenue across quarters with AI-generated charts
- Spot insider buying ahead of new mask launches using our ResMed earnings report filing analysis
- Monitor product-recall language or patent disputes the minute they appear in an 8-K
ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.
On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. (RMD) filed a Form 4 disclosing that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025. These shares came from performance-based restricted stock units that were originally granted on November 16, 2022 and were earned when the compensation and leadership development committee certified that the performance targets were met.
After this transaction, the officer beneficially owns 29,028 shares of ResMed common stock in direct ownership. The transaction was reported as an acquisition at a price of $0, reflecting the vesting of equity compensation rather than an open-market purchase.
ResMed Inc. (RMD) reported a director equity grant on a Form 4. On 11/20/2025, a company director acquired 1,073 shares of ResMed common stock through a stock award at a stated price of $0 per share, reflecting a grant of restricted stock units.
After this transaction, the reporting person beneficially owned 5,118 shares of ResMed common stock in direct ownership. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.
ResMed Inc. (RMD) reported an insider equity award for director Nicole Mowad-Nassar on a Form 4. On 11/20/2025, she received 536 shares of ResMed common stock as a grant of restricted stock units at a stated price of $0 per share, reflecting a stock-based award rather than an open-market purchase. Following this transaction, she beneficially owned 777 shares directly.
The filing notes that these restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders held in the year following the grant date. This is a routine director compensation transaction and does not involve any derivative securities.
ResMed Inc. director Desney Tan reported receiving a new equity award from the company. On 11/20/2025, he acquired 1,073 shares of ResMed common stock through a grant priced at $0, increasing his directly owned stake to 6,002 shares after the transaction.
The award is in the form of restricted stock units (RSUs), which are shares that Tan will receive once they vest. These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, meaning the shares are subject to a service-based vesting condition tied to time and board tenure.
ResMed Inc. (RMD)Harjit Gill received an equity award in the form of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025. The RSUs were granted at a price of $0 per unit, reflecting a typical director equity grant rather than an open‑market purchase.
After this award, Gill beneficially owns 10,940 shares of ResMed common stock. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to continued board service over roughly a one‑year cycle.
ResMed Inc. (RMD) reported an equity grant to director Karen Drexler. On 11/20/2025, she acquired 1,073 shares of ResMed common stock through a grant of restricted stock units at a stated price of
The restricted stock units vest in full on the earlier of
ResMed Inc. (RMD) director Carol Burt reported a grant of 1,073 shares of ResMed common stock in the form of restricted stock units. These RSUs were awarded on 11/20/2025 at a price of $0 per share, reflecting a typical equity compensation grant for a board member rather than an open-market purchase.
Following this award, she reported 2,156 shares of ResMed common stock held directly and an additional 16,660 shares held indirectly through the Carol Burt Hilliard Trust. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to her continued board service.
ResMed Inc. (RMD) reported a change in director ownership through a Form 4 filing. Director Ronald Taylor received an award of 1,073 shares of ResMed common stock on 11/20/2025 at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 24,771 shares directly.
The shares awarded are in the form of Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with the company’s long-term performance and shareholder interests.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
